A hormonal level estimation in men treated due to testicular neoplasm
Article published in Urologia Polska 2002/55/4.

authors

Tomasz Demkow: Klinika Nowotworów Układu Moczowego Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie w Warszawie Kierownik kliniki: dr hab. Tomasz Demkow

keywords

testis, cancer of the testis, chemotherapy, FSH, LH, testosteron, prolactin, progesterone, estradiol

summary

Aim of the study. Tlie aim of this study is to estimate the relationship between the treatment of testicular neoplasm (e.g. radical orchidectomy and platine based chemotherapy) and the level of follicle stimulating hormone (FSH), luteotrophic hormone (LH), testosterone, estradiol, progesterone and prolactine in men treated due to testicular neoplasm.

Material. Tlie group of 50 testicular neoplasm patients was examined. In all of them the hormone levels were estimated before orchidectomy and 3, 6,12,18,24, and 30 months after operation. It was a prospective study.

Results. Radical orchidectomy performed due to testicular neoplasm caused decreasing the levels of estradiol (p< 0.001) and testosterone (p<0.001) and increasing levels of LH and FSH (p<0.001). The levels of the other examined hormones were not changed, hi patients who underwent chemotherapy the levels o f FSH and LH significantly increased. Statistically significant increase of testosterone levels were observed 24 and 30 months after chemotherapy. Hie levels of the other hormones were stable after therapy.

Conclusions.

1. Orchidectomy performed due to testicular neoplasm leads to desrease levels of estradiol and testosterone, and increase levels of LH and FSH.

2. Platine based chemotherapy leads to maintenance the increased levels of FSH and LH during 30 months after the end of the treatment.

3. The level of FSH is inversely proportional with the sperm cells number in 1 ml of the sperm before and after chemotherapy due to testicular neoplasm.

references

1. Madej G: Zasady postępowania diagnostycznego i leczenia. CentrumOnkologii - Instytut, Warszawa, 1995, str. 4.
2. Krcuser ED, I larsch U, Hetzel WD, et al: Chronic gonadal toxicityin patients with testicular cancer after chemotherapy. Eur J Cancer 1986; 22,3:289-294.
3. Brenneman W, Stoffel-Wagner B, Wischers M: Pre-treatment folliculostimulating hormone: a prognostic serum marker of spermatogenesis status in patients treated for germ cell cancer. J Urol 1998; 159: 1942-1946.
4. Fossa S, Aabyholm T, Vespestad S, et al: Semen quality after treatment for testicular cancer. Eur Urol 1993; 23: 172-176.
5. Hansen SW, Berthelsen JG, von der Maase H: Long-term fertilityand Leydig cell function in patients treated for germ cell cancer with cispiatin, vinblastine, and bleomycin versus surveillance. J Clin One 1990;8:1695-1698.
6. Stuart NSA, Woodroffe R, Cullen MH:Long-term toxicity of chemo-therapy for testicular cancer- the cost of cure. Br J Cancer 1990; 61: 479-484.
7. Fossa SD, Theodorsen L Norman N:Recovery of impairedpretreatmentspeimalogenesis in testicular cancer. Fertil Steril 1990; 54:493-496.
8. Drasga RE, Einhorn LH, Williams et al: Fertility after chemotherapyfor testicular cancer. J Clin Oncol 1983; 1:179-183.
9. Fossa SD, Ons S, Abyholm T:Post-treatment fertility in patients withtesticular cancer. Cancer 1985; 47:210-214.
10. Grigor KM, Donohue JP: Reproductive aspects of testicular germ cell cancer:general discussion. Eur Urol 1993; 23:177-181.
11. Petersen MP, Skakkebaek NE, Roth M, et al: Semen quality and reproductive hormones before and after orcliidectomy in men with testicular cancer. J Urol 1999; 161: 822-826.
12. Nijman JM, Schaflbrdt Koops H, Krcmcr J: Gonadal function after surgeiy and chemotherapy in men with stage 11 and 111 nonsemino-matous testicular tumors. J Clin Oncol 1987; 5: 651-656.
13. DeKretscr DM, Burger HG, Hudson B:The relationship between germinal cells and serum FSH levels in male with infertility. J Clin Endocr Metab 1974; 35:12-17.
14. Palmieri G, Lotrecchiano G, Ricci G, el al: Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 1996; 134:431-436.
15. Giagulli VA, Vermculcn A: Leydig cell function in infertile men with idiopathic oligospermic infertility. J Clin Endocr Metab 1988; 66: 62-76.
16. Willemse PHB, Slcifcr DTh, Sluiter \\\'W]: Altered Leydig cell function inpatients with testicular cancer:evidence for a bilateral testicular defect. Acta Endocrinologica 1983; 102:16-624.
17. Petersen PM, Skakkebaek NE, Vistisen K, et al: Semen quality and reproductive hormones before orchidectomy in men with testicular cancer. J Clin Oncol 1999; 17, 3: 941-947.
18. Aass N, Fossa DS, Theodorsen L, at al: Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 199; 27:1087-1091.
19. Hansen PV, Trykkcr H, Helkjaer PE, et al: Testicular function inpatients with testicular cancer treated with orchidectomy alone or orchidectomy plus Cisplatin-based chemotherapy. J. Natl Cancer Insl 1989;81:1246-1250.
20. Willemse PHB, Sleijfer Koops H, et al: Leydig cell function inpatients with testicular cancer during and after chemotherapy. Internal Journal of Andrology 1983; 6: 497-508.
21. Bosi GJ, Bajorunas D: Pituitary and testicular hormonal function after treatment for germ cell ntmours. Internal Journal of Andrology 1987; 10:381-384.
22. LeBlanc GA, Kantoff WP, Ng S, et al:Hormonal peiturbatione in patients with testicular cancer treated with cisplatin. Cancer 1992; 69,9:2306-2310.
23. Carlson HE: Gynecomastia. N Eng J Med 1980; 303: 795-799.
24. Forest MG, Lccoq A, Saez JM:Kinetics of human chorionic gona-dotropin-induced steroidogenic response of human testis. J Clin En-do Crinol Metab 1979; 49: 284-291.
25. Stuarl P, Lcitncr P, George J, el al: Gonadal dysfunction inpatients for metastatic germ-cell tumors. Journal of Clinical Oncology 1986; 4,10:1500-1505.

correspondence